202 related articles for article (PubMed ID: 33754891)
21. FDA Approval Summary: (Daunorubicin and Cytarabine) Liposome for Injection for the Treatment of Adults with High-Risk Acute Myeloid Leukemia.
Krauss AC; Gao X; Li L; Manning ML; Patel P; Fu W; Janoria KG; Gieser G; Bateman DA; Przepiorka D; Shen YL; Shord SS; Sheth CM; Banerjee A; Liu J; Goldberg KB; Farrell AT; Blumenthal GM; Pazdur R
Clin Cancer Res; 2019 May; 25(9):2685-2690. PubMed ID: 30541745
[TBL] [Abstract][Full Text] [Related]
22. AML with Myelodysplasia-Related Changes: Development, Challenges, and Treatment Advances.
Koenig KL; Sahasrabudhe KD; Sigmund AM; Bhatnagar B
Genes (Basel); 2020 Jul; 11(8):. PubMed ID: 32722092
[TBL] [Abstract][Full Text] [Related]
23. Effects of lenalidomide on the bone marrow microenvironment in acute myeloid leukemia: Translational analysis of the HOVON103 AML/SAKK30/10 Swiss trial cohort.
Brune MM; Stüssi G; Lundberg P; Vela V; Heim D; Manz MG; Haralambieva E; Pabst T; Banz Y; Bargetzi M; Grobholz R; Fehr M; Cogliatti S; Ossenkoppele GJ; Löwenberg B; Rudolf CB; Li Q; Passweg J; Mazzuchelli L; Medinger M; Tzankov A;
Ann Hematol; 2021 May; 100(5):1169-1179. PubMed ID: 33704530
[TBL] [Abstract][Full Text] [Related]
24. [Synergistic Mechanism of Interferon alpha-1b, Interleukin-2 and Thalidomide for Immune Regulation in Patients with Acute Myeloid Leukemia].
Mi RH; Chen L; Zhou YL; Li DB; Liu S; Wang XJ; Liu J; Wang MF; Ma XM; Li ZC; Zhao HM; Xu YL; Chen SX; Yang HP; Guo ZQ; Luan CL; Guo SL; Song QL; Wei XD
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Feb; 29(1):26-31. PubMed ID: 33554792
[TBL] [Abstract][Full Text] [Related]
25. Acute myelogenous leukemia in elderly patients not eligible for intensive chemotherapy: the dark side of the moon.
Latagliata R; Bongarzoni V; Carmosino I; Mengarelli A; Breccia M; Borza PA; D'Andrea M; D'Elia GM; Mecarocci S; Morano SG; Petti MC; Mandelli F; Alimena G
Ann Oncol; 2006 Feb; 17(2):281-5. PubMed ID: 16373393
[TBL] [Abstract][Full Text] [Related]
26. Green tea polyphenols change the profile of inflammatory cytokine release from lymphocytes of obese and lean rats and protect against oxidative damage.
Molina N; Bolin AP; Otton R
Int Immunopharmacol; 2015 Oct; 28(2):985-96. PubMed ID: 26299975
[TBL] [Abstract][Full Text] [Related]
27. Phase I study of cladribine, cytarabine (Ara-C), granulocyte colony stimulating factor (G-CSF) (CLAG Regimen) and simultaneous escalating doses of imatinib mesylate (Gleevec) in relapsed/refractory AML.
Walker AR; Komrokji RS; Ifthikharuddin J; Messina P; Mulford D; Becker M; Friedberg J; Oliva J; Phillips G; Liesveld JL; Abboud C
Leuk Res; 2008 Dec; 32(12):1830-6. PubMed ID: 18571721
[TBL] [Abstract][Full Text] [Related]
28. The imbalanced profile and clinical significance of T helper associated cytokines in bone marrow microenvironment of the patients with acute myeloid leukemia.
Sun YX; Kong HL; Liu CF; Yu S; Tian T; Ma DX; Ji CY
Hum Immunol; 2014 Feb; 75(2):113-8. PubMed ID: 24269703
[TBL] [Abstract][Full Text] [Related]
29. Low-dose lenalidomide plus cytarabine in very elderly, unfit acute myeloid leukemia patients: Final result of a phase II study.
Visani G; Ferrara F; Di Raimondo F; Loscocco F; Fuligni F; Paolini S; Zammit V; Spina E; Rocchi M; Visani A; Piccaluga PP; Isidori A
Leuk Res; 2017 Nov; 62():77-83. PubMed ID: 28987821
[TBL] [Abstract][Full Text] [Related]
30. [Regulation Effect of Myeloid Leukemia No.1 Chinese Herb Medicine Prescription Combined with Chemotherapy on Th17 Cells in Bone Marrow of Patients with Acute Myeloid Leukemia].
Zhang GL; Pan M; Wang YZ; Huang JX; Gu GS; Wang Y; Wu Q; Yao LT; Xie HR; Hu XJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Apr; 29(2):328-332. PubMed ID: 33812395
[TBL] [Abstract][Full Text] [Related]
31. Low-dose decitabine priming with intermediate-dose cytarabine followed by umbilical cord blood infusion as consolidation therapy for elderly patients with acute myeloid leukemia: a phase II single-arm study.
Li X; Dong Y; Li Y; Ren R; Wu W; Zhu H; Zhang Y; Hu J; Li J
BMC Cancer; 2019 Aug; 19(1):819. PubMed ID: 31429724
[TBL] [Abstract][Full Text] [Related]
32. The CCL2/CCR2 Axis Affects Transmigration and Proliferation but Not Resistance to Chemotherapy of Acute Myeloid Leukemia Cells.
Macanas-Pirard P; Quezada T; Navarrete L; Broekhuizen R; Leisewitz A; Nervi B; Ramírez PA
PLoS One; 2017; 12(1):e0168888. PubMed ID: 28045930
[TBL] [Abstract][Full Text] [Related]
33. TGF-β1 and CXCL12 modulate proliferation and chemotherapy sensitivity of acute myeloid leukemia cells co-cultured with multipotent mesenchymal stromal cells.
Schelker RC; Iberl S; Müller G; Hart C; Herr W; Grassinger J
Hematology; 2018 Jul; 23(6):337-345. PubMed ID: 29140182
[TBL] [Abstract][Full Text] [Related]
34. Epigenetic priming with decitabine followed by low dose idarubicin and cytarabine in acute myeloid leukemia evolving from myelodysplastic syndromes and higher-risk myelodysplastic syndromes: a prospective multicenter single-arm trial.
Zhou X; Mei C; Zhang J; Lu Y; Lan J; Lin S; Zhang Y; Kuang Y; Ren Y; Ma L; Wei J; Ye L; Xu W; Li K; Lu C; Jin J; Tong H
Hematol Oncol; 2020 Oct; 38(4):531-540. PubMed ID: 32469434
[TBL] [Abstract][Full Text] [Related]
35. Comparison of Reduced-Intensity Idarubicin and Daunorubicin Plus Cytarabine as Induction Chemotherapy for Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia.
Liu H; Fu R; Li L; Wang G; Song J; Ruan E; Wang H; Wu Y; Wang X; Ding K; Shao Z
Clin Drug Investig; 2017 Feb; 37(2):167-174. PubMed ID: 27722823
[TBL] [Abstract][Full Text] [Related]
36. CPX-351 (vyxeos) in AML.
Alfayez M; Kantarjian H; Kadia T; Ravandi-Kashani F; Daver N
Leuk Lymphoma; 2020 Feb; 61(2):288-297. PubMed ID: 31547736
[TBL] [Abstract][Full Text] [Related]
37. Long-term outcome of high-dose cytarabine-based consolidation chemotherapy for older patients with acute myelogenous leukemia.
Schiller G; Lee M
Leuk Lymphoma; 1997 Mar; 25(1-2):111-9. PubMed ID: 9130619
[TBL] [Abstract][Full Text] [Related]
38. [Venetoclax with low-dose cytarabine for patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy: results from the Chinese cohort of a phase three randomized placebo-controlled trial].
Hu Y; Jin J; Zhang Y; Hu JD; Li JM; Wei XD; Gao SJ; Zha JH; Jiang Q; Wu J; Mendes W; Wei AH; Wang JX
Zhonghua Xue Ye Xue Za Zhi; 2021 Apr; 42(4):288-294. PubMed ID: 33979972
[No Abstract] [Full Text] [Related]
39. Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trial.
Heuser M; Smith BD; Fiedler W; Sekeres MA; Montesinos P; Leber B; Merchant A; Papayannidis C; Pérez-Simón JA; Hoang CJ; O'Brien T; Ma WW; Zeremski M; O'Connell A; Chan G; Cortes JE
Ann Hematol; 2021 May; 100(5):1181-1194. PubMed ID: 33740113
[TBL] [Abstract][Full Text] [Related]
40. Postremission therapy with low-dose interleukin 2 with or without intermediate pulse dose interleukin 2 therapy is well tolerated in elderly patients with acute myeloid leukemia: Cancer and Leukemia Group B study 9420.
Farag SS; George SL; Lee EJ; Baer M; Dodge RK; Becknell B; Fehniger TA; Silverman LR; Crawford J; Bloomfield CD; Larson RA; Schiffer CA; Caligiuri MA
Clin Cancer Res; 2002 Sep; 8(9):2812-9. PubMed ID: 12231521
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
